Fritextsökning
Innehållstyper
-
Emerson
-
The US is leaving the WHO
The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.
-
ZEISS presents the "Quality Innovation Days"
The digital event for metrology and software.
-
Superconductor technology: Contactless working in the laboratory of the future
Automated filling and weighing of freeze-dry containers in the cleanroom with SupraMotion from Festo
-
AI automates testing of implant coatings
The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.
-
Mastering Urine Microscopy: Techniques for Accurate Disease Detection
Live Webinar on September 25, 2024.
-
Ytterligare läkemedelskandidat mot Alzheimers droppas
Ett litet schweiziskt biotechbolag avbryter en fas II-studien med sin läkemedelskandidat mot Alzheimers sjukdom. Beskedet kommer inte långt efter att Biogen och...
-
Government apoints new experts to medicine and health council
Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Counci...
-
“You discover one thing – and then 10 new questions arise”
COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current fo...
-
“A major energy boost for the entire cancer vaccine field”
The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...
-
Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”
It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or wheth...
-
AstraZeneca to use American AI platform for cancer trials
In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
Revealing the secrets of a part
CT inspection in automation technology at Festo.
-
Isländskt läkemedelsbolag noterar sig på Stockholmsbörsen - ”Naturligt steg”
Ett av Islands största företag, läkemedelsbolaget Alvotech, planerar att notera sig på Nasdaq Stockholm.
-
Anna Törner: The clinical trial – Periscope to reality
What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.
-
Meet us at Control 2025
Innovations that drive efficiency.
-
Recipharm divests five Swedish plants
Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity compa...
-
Studie: Uppväxtort kan påverka risk för typ 1-diabetes
Risken att utveckla diabetes typ 1 varierar kraftigt beroende på var i Sverige du har bott som barn, enligt en ny studie från Göteborgs universitet. Resultatet ...
-
Petter Hartman: ”Existentiell egenvård i en kaotisk värld”
”Vår förmåga att möta livets svårigheter tycks hänga ihop med känslan av gemenskap och meningsfullhet”, skriver Petter Hartman i en krönika som tar upp regering...
-
Pneumatics Makes a Technological Leap with Piezo
The first high-precision proportional valve terminal VTEP opens up new application areas
-
MedVasc and Scientific Solutions join forces to streamline FDA 510(k) regulatory process
MedVasc, an exciting MedTech startup company, and Scientific Solutions, a renowned consulting firm within Life Science, are pleased to announce a strategic part...
-
Pharma Relations AB